Vaxart completes sentinel cohort enrollment in Phase 2b oral COVID vaccine trial

Vaxart, Inc.

Sentinel cohort of 400 participants randomized 1:1 to Vaxart's oral pill vaccine or approved mRNA comparator.
Last dose administered Nov 26, 2024; DSMB and FDA will review 30-day safety data before expanding.
Upon favorable review and BARDA approval, second part will enroll approximately 10,000 participants.
Project NextGen award (BARDA) valued at up to $456 million; trial includes >=25% over age 65.
Primary endpoint is relative efficacy vs mRNA comparator for prevention of symptomatic COVID-19 disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.